Navigation Links
FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
Date:2/27/2009

onia (e.g., bronchitis) was higher for SYMBICORT than placebo.

SYMBICORT is not a rescue medication and does not replace fast-acting inhalers to treat acute symptoms.

SYMBICORT should not be initiated in patients during rapidly deteriorating or potentially life-threatening episodes of asthma or COPD.

Patients who are receiving SYMBICORT should not use additional formoterol or other long-acting inhaled beta2-agonists for any reason.

Excessive beta-adrenergic stimulation has been associated with central nervous system and cardiovascular effects. SYMBICORT, like all products containing sympathomimetic amines, should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrhythmias, and hypertension. Some patients may experience an increase in blood pressure or heart rate.

The most common adverse events greater than or equal to 3% reported in COPD clinical trials included nasopharyngitis, oral candidiasis, bronchitis, sinusitis and upper respiratory tract infection.

Common adverse events reported in asthma clinical trials, occurring in greater than or equal to 5% of patients, included nasopharyngitis, headache, upper respiratory tract infection, pharyngolaryngeal pain, sinusitis, and stomach discomfort.

Particular care is needed for patients being transferred from systemically active corticosteroids to inhaled corticosteroids.

WARNING: Long-acting beta2-adrenergic agonists may increase the risk of asthma-related death. Therefore, when treating patients with asthma, SYMBICORT should only be used for patients with asthma not adequately controlled on other asthma-controller medications (eg, low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with two maintenance therapies. Data from a large placebo-controlled US'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
2. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
3. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
4. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
5. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers
6. FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
7. Bion Announces PENNVEST Board Approves $7.8 Million Financing for Kreider Farms Dairy Project
8. Monsanto Board Approves 10 Percent Dividend Increase
9. FDA Approves Most Comprehensive System to Test Donated Blood for HIV, Hepatitis B & Hepatitis C
10. MultiVu Video Feed: U.S Food and Drug Administration (Fda) Approves Latisse(TM) --
11. FDA Approves Boston Scientifics Express(R) SD Renal Stent System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... October 20, 2014 OCTOBER ... Meeting (ABIM). ABIM will take place ... information about ABIM 2014 is now available ... Delegates representing companies and organizations from all ... obtain information on the latest products and ...
(Date:10/19/2014)... The report "Chocolate, Cocoa Beans, Lecithin, Sugar and Vanilla ... Forecast (2011 - 2016)," analyzes the chocolate market ... major market drivers, restraints, and opportunities for the chocolate ... global chocolate market is expected to grow from $83.2 ... estimated CAGR of 2.7% from 2011 to 2016. , ...
(Date:10/18/2014)... The Asia-Pacific Bio-based Advanced Phase ... bio-based advanced phase change material market in Asia-Pacific ... through the TOC of the Asia-Pacific Bio-based Advanced ... idea of the in-depth analysis provided. This also ... Asia-Pacific bio-based advanced phase change material market, and ...
(Date:10/18/2014)... 18, 2014 The Asian Electronic Medical Record ... Asian with analysis and forecast of revenue. The electronic medical ... to $2,328.0 million by 2018, at a CAGR of 9.4% ... the Asian Electronic Medical Record (EMR) market, to get an ... glimpse of the segmentation of the market in the same ...
Breaking Biology Technology:Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bio-based Advanced Phase Change Materials Market is estimated to grow to $39.8 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 2The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 3The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 4The Asian Electronic Medical Record (EMR) market is estimated to grow to $2,328.0 million by 2018 - New Report by MicroMarket Monitor 5
... t2cure, a clinical,stage biopharmaceutical company developing novel regenerative ... it has appointed,Dr. Petra Rueck Head of Clinical ... join our company", said Manfred Ruediger,CEO of t2cure. ... be of critical importance to t2cure as we ...
... DIEGO, Feb. 25 Speid & Associates, a ... hosting,a six session Webinar series on diabetes and ... April. Speakers will include former Food and,Drug Administration ... as,well as a distinguished list of other guest ...
... BOSTON, Feb. 25 Experts from PAREXEL,International ... global,bio/pharmaceutical services provider, will present on key ... Annual EuroMeeting in Barcelona,Spain being held March ... from,presentations by some of PAREXEL,s thought leaders, ...
Cached Biology Technology:Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 2PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 3PAREXEL to Present Leading Insights Regarding Key Industry Topics at 20th Annual Drug Information Association EuroMeeting 4
(Date:10/16/2014)... at William and Mary,s Virginia Institute of Marine ... the Environmental Protection Agency to identify the streams ... to develop tools to help local governments and ... depends critically on a dataset of tidal-marsh observations ... Only with this historical baseline can today,s researchers ...
(Date:10/16/2014)... causes severe respiratory tract infections and worldwide claims ... at VIB and Ghent University have succeeded in ... common virus infection. , Xavier Saelens (VIB/UGent): ... the way for the development of a novel ... causes suffering in numerous small children and elderly ...
(Date:10/15/2014)... to assess the pandemic risk from strains of influenza ... not allow ourselves to become complacent that the most ... of scientists. , Influenza pandemics arise when a new ... develop widespread immunity – spreads in the human population. ... 100 years, the worst of which – the 1918 ...
Breaking Biology News(10 mins):EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3New perspectives for development of an RSV vaccine 2Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2
... Drawing on records dating back to the journals of Henry ... plant families near Walden Pond have borne the effects of ... families hit hardest by global warming have included beloved species ... appears this week in the Proceedings of the National ...
... used to treat type 2 diabetes may be more likely ... at Washington University School of Medicine in St. Louis have ... drugs, sulfonylureas, help type 2 diabetics make more insulin, improving ... effects of sulfonylureas are lost after several years of use, ...
... carriers of avian influenza viruses from continent to continent ... has important implications for highly pathogenic avian influenza virus ... multi-pronged research effort to understand the role of migratory ... Asia and North America, scientists with the U.S. Geological ...
Cached Biology News:Effects of climate change vary greatly across plant families 2Moderate use averts failure of type 2 diabetes drugs in animal model 2Genetic evidence for avian influenza movement from Asia to North America via wild birds 2
... to PRKAR2 cAMP is a signaling ... functions. cAMP exerts its effects by activating ... the signal through phosphorylation of different target ... a tetramer composed of two regulatory and ...
...
... a Perkin Elmer UltraVIEW system and want to ... and iQ software? No problem. Our experienced ... your existing microscope, lasers, Sutter filter wheel, Piezo ... work with our precision controller unit and workstation... ...
... instrument is the most advanced thermal cycler ... thermal performance, the Dyad also boasts graphical ... point-and-click navigation via touch pad or mouse. ... and economically expanded to a four-bay system ...
Biology Products: